Docetaxel is a novel semisynthetic taxoid obtained from 10-deaceryl baccatin III. a precursor extracted from the needles of the European yew, Taxus baccata. It has demonstrated activity against a variety of preclinical tumour models (Bissery et al., 1991) . In fact, at equitoxic doses, it proved to be more active than paclitaxel (Taxol) against B16 murine melanoma (Bissery et al., 1991) .
Docetaxel works as an antimitotic agent, enhancing microtubule assembly and inhibiting depolymerisation of tubulin, resulting in the inability of cells to divide (Gueritte-Voegelein et al., 1991; Ringel & Horwitz, 1991) .
The dose-limiting toxicity of docetaxel in all schedules tested in phase I clinical trials was neutropenia, but dermatitis and stomatitis were also frequently observed (Rousseau et al., 1991; Tomiak et al., 1991; Bruno et al., 1992; Bissett et al., 1992; Pazdur et al., 1992; de Valeriola et al., 1992; Bum's et al., 1993) . When given as a 1 h infusion every 3 weeks, dose-limiting oral mucositis did not occur.
The maximal tolerated dose (MTD) for a single dose administration ranged between 90 and 115mgm-2. The highest dose intensity was reached with the 1 h every 3 weeks schedule compared with weekly administrations. Thus, this schedule was selected for phase II clinical trials.
Carcinoma of the stomach remains one of the leading causes of cancer-related deaths (Silverberg, 1985) . Despite maximal surgical efforts, results after resection of gastric tumours are frequently dismal. A number of chemotherapeutic agents are active in advanced, metastatic carcinoma of the stomach (Kelsen, 1988) . However, for most trials with different combinations including the most active single agents, response rates remain low, with median duration of response ranging between 6 and 9 months and with median survival of responders reaching less than 1 year (Macdonald et al., 1980; Wils et al., 1986 If grade 2-3 skin toxicity occurred, doses of docetaxel were reduced by 25%. Moreover, subsequent administrations were delayed up to 1 week, until recovery to < grade 1 toxicity.
The rate of infusion of docetaxel was decreased for mild hypersensitivity reactions (HSRs), such as localised cutaneous findings (flush, rash, pruritus, etc.). For more pronounced symptoms, including generalised pruritus, flushing and rash, dyspnoea and hypotension with systolic blood pressure >80 mmHg, the docetaxel infusion was stopped and intravenous antihistamines and steroids were administered. The infusion of docetaxel was continued after symptom recovery.
In the event of a severe HSR, with bronchospasm, generalised urticaria, angio-oedema or hypotension below 80 mmHg systolic, the docetaxel infusion was stopped and antihistamines and steroids were given i.v. Docetaxel infusion was restarted within 72 h using premedication with antihistamines and steroids, and this was then repeated with each subsequent cycle.
A partial remission was defined as a decrease of at least 50% in the sum of the products of the largest perpendicular diameters of measurable lesions as determined in two observations, not less than 4 weeks apart, in the absence of an increase in any of the known lesions or the appearance of a new one.
Stabilisation of disease required less than 50% decrease or less than 25% increase in the sum of the product of the longest perpendicular diameters of all measurable lesions without the appearance of a new lesion.
Patients had to receive at least two courses of docetaxel to be evaluable for response; the anti-tumour effect of docetaxel was assessed every two cycles. Response duration and survival were calculated from the onset of docetaxel therapy.
Resdts
A total of 42 patients with advanced gastric cancer were entered into the study. Of the 42 patients, five were considered ineligible: two lacked clearly measurable disease, one had his baseline work-up performed more than 3 weeks prior to the onset of docetaxel chemotherapy, one patient had an elevated bilirubin and the fifth patient did not meet the eligibility criteria because of lack of informed consent and therefore did not receive treatment
The main characteristics of the 37 eligible patients are depicted in Table I . The median PS was 1, and the most common metastatic sites were the liver and the retroperitoneum. In 18 patients (49%), the primary tumour had not been surgically removed; in the remaining patients, the interval between surgery and docetaxel chemotherapy ranged from 3 weeks to 60 months (median 8 months).
None of the patients had received chemotherapy prior to docetaxel. Toxicity Overall, 156 cycles of docetaxel were delivered to these patients for a median of four cycles per patient (range 1-8). Dose reduction was necessary in 30 cycles (19%) given to eight patients, mainly because of myelosuppression or scin toxicity; doses were decreased to 75mgm-2 in 16 courses and to 55 mg m 2 in 14. The full dose of 100 mg m 2 could be given as originally planned in the remaining 126 courses (81%). Delay in the administration of docetaxel was necessary in 14 cycles (9%), for a median of 3 days and never more than 7 days.
Haematological and non-haematological toxicities are summarised in Tables II and III Weight gain of > 2 kg was recorded in 8 of the 37 patients, all of whom had received four cycles or more of docetaxel. This was due to fluid retention, which resulted in peripheral oedema and sometimes pleural effusions (transudates). The median weight gain in these eight patients was 6.2 kg (range 2-13 kg).
Three cardiac events (two supraventricular arrhythmias in the form of paroxysmal atrial tachycardia and atrial fibrillation and one episode of coronary ischaemia) occurred in two patients while on docetaxel chemotherapy. The supraventricular arrhythmias occurred on day 4 of the first cycle and on day 8 of the second cycle of docetaxel, and subsided in both patients with conventional therapy. Both patients were uneventfully rechallenged with docetaxel.
Anti-tumour activity
Eight patients achieved a partial remission; seven of these eight responses have been externally and independently reviewed and confirmed. The median duration of response was 7.5 months (range, 3 to 11 + months) (Table IV) . Responses occurred in a variety of metastatic sites (Table V) including the liver (one patient), retroperitoneum (three patients), soft-tissue masses in the abdominal wall (one patient) and in the neck and mediastinum (one patient). One patient had multiple cutaneous nodules, and in another patient the primary tumour site responded to docetaxel. None of the remaining patients who had not undergone gastrectomy responded at the primary site.
Eleven patients had stabilisation of disease for a median of 4 months (range 3-8 months). Disease progression occurred in 14 patients, including three patients in whom progression was documented during the first 6 weeks of docetaxel chemotherapy ('early progression'). Response could not be assessed in the remaining four patients: one refused further docetaxel chemotherapy following the first administration, one patient died suddenly at home of unknown causes on day 14 While most cycles of docetaxel were given according to the originally planned dose and schedule, a wide variety of sideeffects were recorded. Neutropenia represented the major toxicity for most patients; nevertheless, there were only eight episodes (5%) of leucopenic fever requiring hospital admission, reflecting the prompt recovery of the leucocyte count.
The non-haematological side-effects included dermatological reactions as well as mild to moderate HSRs, which were subsequently controlled with antiallergic premedication and never led to the discontinuation of docetaxel. Some patients complained of fatigue and myalgias while on treatment with docetaxel. Most troublesome, however, was the development of a fluid retention syndrome, observed mainly in patients receiving four or more cycles of docetaxel and characterised by weight gain, peripheral oedema and pleural effusion. This syndrome has also been observed in other phase II trials with docetaxel carried out by the ECTG, a detailed description of which is reported elsewhere (Wanders et al., 1993) ; preliminary data suggest that corticosteroids might benefit these patients to some extent.
There has been a growing disappointment with the use of drug combinations such as FAM (Biran et al., 1989) or, more recently, EAP (Taal et al., 1990) in the treatment of advanced gastric cancer, making the need for novel, active and, hopefully, less toxic combinations urgent. Recently, the use of paclitaxel in 20 patients with advanced adenocarcinomas of the upper gastrointestinal tract resulted in only one partial remission (Einzig et al., 1993) . In contrast, the present study does inidcate definite activity for docetaxel, and the difference may partly be explained by the extent of prior chemotherapy.
Further clinical investigations with docetaxel in patients with carcinoma of the stomach are certainly warranted based on the experience reported here, including the use of docetaxel in combination with other active drugs in this disease, such as the anthracyclines, 5-fluorouracil and others. Other possible venues for investigation include the routine use of premedication to circumvent HSRs and the fluid retention syndrome, and the concomitant administration of granulocyte colony-stimulating factor (G-CSF).
These investigations shall define the precise role of docetaxel in the overall treatment of gastric cancer.
